TY  - JOUR
AU  - Miladinov, Marko
AU  - Rosić, Jovana
AU  - Erić, Katarina
AU  - Guzonjić, Azra
AU  - Jelenković, Jelenko
AU  - Bogavac-Stanojević, Nataša
AU  - Dimitrijević, Ivan
AU  - Kotur-Stevuljević, Jelena
AU  - Barišić, Goran
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5204
AB  - The Schlafen 11 (SLFN11) protein has recently emerged as pivotal in DNA damage conditions, with predictive potential for tumor response to cytotoxic chemotherapies. Recent discoveries also showed that the programmed death ligand 1 (PD-L1) protein can be found on malignant cells, providing an immune evasion mechanism exploited by different tumors. Additionally, excessive generation of free radicals, redox imbalance, and consequential DNA damage can affect intestinal cell homeostasis and lead to neoplastic transformation. Therefore, our study aimed to investigate the significance of SLFN11 and PD-L1 proteins and redox status parameters as prognostic biomarkers in CRC patients. This study included a total of 155 CRC patients. SLFN11 and PD-L1 serum levels were measured with ELISA and evaluated based on redox status parameters, sociodemographic and clinical characteristics, and survival. The following redox status parameters were investigated: spectrophotometrically measured superoxide dismutase (SOD), sulfhydryl (SH) groups, advanced oxidation protein products (AOPP), malondialdehyde (MDA), pro-oxidant–antioxidant balance (PAB), and superoxide anion (O2•–). The prooxidative score, antioxidative score, and OXY-SCORE were also calculated. The results showed significantly shorter survival in patients with higher OXY-SCOREs and higher levels of serum SLFN11, while only histopathology-analysis-related factors showed significant prognostic value. OXY-SCORE and SLFN11 levels may harbor prognostic potential in CRC patients.
PB  - MDPI
T2  - International Journal of Molecular Sciences
T1  - Analysis of the Prognostic Potential of Schlafen 11, Programmed Death Ligand 1, and Redox Status in Colorectal Cancer Patients
VL  - 24
IS  - 20
DO  - 10.3390/ijms242015083
ER  - 

@article{
author = "Miladinov, Marko and Rosić, Jovana and Erić, Katarina and Guzonjić, Azra and Jelenković, Jelenko and Bogavac-Stanojević, Nataša and Dimitrijević, Ivan and Kotur-Stevuljević, Jelena and Barišić, Goran",
year = "2023",
abstract = "The Schlafen 11 (SLFN11) protein has recently emerged as pivotal in DNA damage conditions, with predictive potential for tumor response to cytotoxic chemotherapies. Recent discoveries also showed that the programmed death ligand 1 (PD-L1) protein can be found on malignant cells, providing an immune evasion mechanism exploited by different tumors. Additionally, excessive generation of free radicals, redox imbalance, and consequential DNA damage can affect intestinal cell homeostasis and lead to neoplastic transformation. Therefore, our study aimed to investigate the significance of SLFN11 and PD-L1 proteins and redox status parameters as prognostic biomarkers in CRC patients. This study included a total of 155 CRC patients. SLFN11 and PD-L1 serum levels were measured with ELISA and evaluated based on redox status parameters, sociodemographic and clinical characteristics, and survival. The following redox status parameters were investigated: spectrophotometrically measured superoxide dismutase (SOD), sulfhydryl (SH) groups, advanced oxidation protein products (AOPP), malondialdehyde (MDA), pro-oxidant–antioxidant balance (PAB), and superoxide anion (O2•–). The prooxidative score, antioxidative score, and OXY-SCORE were also calculated. The results showed significantly shorter survival in patients with higher OXY-SCOREs and higher levels of serum SLFN11, while only histopathology-analysis-related factors showed significant prognostic value. OXY-SCORE and SLFN11 levels may harbor prognostic potential in CRC patients.",
publisher = "MDPI",
journal = "International Journal of Molecular Sciences",
title = "Analysis of the Prognostic Potential of Schlafen 11, Programmed Death Ligand 1, and Redox Status in Colorectal Cancer Patients",
volume = "24",
number = "20",
doi = "10.3390/ijms242015083"
}

Miladinov, M., Rosić, J., Erić, K., Guzonjić, A., Jelenković, J., Bogavac-Stanojević, N., Dimitrijević, I., Kotur-Stevuljević, J.,& Barišić, G.. (2023). Analysis of the Prognostic Potential of Schlafen 11, Programmed Death Ligand 1, and Redox Status in Colorectal Cancer Patients. in International Journal of Molecular Sciences
MDPI., 24(20).
https://doi.org/10.3390/ijms242015083

Miladinov M, Rosić J, Erić K, Guzonjić A, Jelenković J, Bogavac-Stanojević N, Dimitrijević I, Kotur-Stevuljević J, Barišić G. Analysis of the Prognostic Potential of Schlafen 11, Programmed Death Ligand 1, and Redox Status in Colorectal Cancer Patients. in International Journal of Molecular Sciences. 2023;24(20).
doi:10.3390/ijms242015083 .

Miladinov, Marko, Rosić, Jovana, Erić, Katarina, Guzonjić, Azra, Jelenković, Jelenko, Bogavac-Stanojević, Nataša, Dimitrijević, Ivan, Kotur-Stevuljević, Jelena, Barišić, Goran, "Analysis of the Prognostic Potential of Schlafen 11, Programmed Death Ligand 1, and Redox Status in Colorectal Cancer Patients" in International Journal of Molecular Sciences, 24, no. 20 (2023),
https://doi.org/10.3390/ijms242015083 . .

TY  - JOUR
AU  - Barišić, Goran
AU  - Anđelkov, Katarina
AU  - Rosić, Jovana
AU  - Miladinov, Marko
AU  - Kotur-Stevuljević, Jelena
AU  - Dinić, Tanja
AU  - Jelenković, Jelenko
AU  - Krivokapić, Zoran
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4092
AB  - Aim: The aim of this study was to investigate whether the application of nanofat contain-ing stem cells improves continence in women who had previously undergone anal sphinc-teroplasty with unsatisfactory long-term outcomes.Method: This  prospective  pilot  study  included  nine  women  with  various  degrees  of  anal incontinence who had previously undergone anal sphincteroplasty due to obstetric trauma.  In  all  patients,  the  Wexner  Incontinence  Score  (WS)  and  Faecal  Incontinence  Quality of Life Score (FIQLS), as well as anal manometry and endoanal ultrasound meas-urements,  were  performed  before  the  procedure  and  during  follow-up.  In  all  patients,  liposuction  was  performed  and  50  ml  of  raw  lipoaspirate  was  obtained  and  processed  using a NanoFat Kit device. Approximately 20 ml of the mechanically emulsified and fil-trated fat was obtained and the anal sphincter complex was infiltrated with it. Patient fol-low-up was conducted in person or via telephone 6 and 12 months after the procedure.Results: The squeeze pressure was significantly increased 6 months after the proce-dure (p= 0.01). The external anal sphincter measured at the 12 o'clock position was sig-nificantly thicker (p= 0.04). A significant decrease in the WS was observed both 6 and 12 months after the procedure compared with baseline values (p< 0.05 for both).Conclusion: This  study  is  the  first  to  show  that  the  application  of  nanofat  as  an  inject-able  product  improves  continence  in  patients  with  unsatisfactory  results  after  sphinc-teroplasty, suggesting it to be a promising and effective therapeutic tool. The procedure is safe and can be easily performed as an ambulatory procedure.
PB  - John Wiley and Sons Inc
T2  - Colorectal Disease
T1  - Application of nanofat for treatment of traumatic faecal incontinence after sphincteroplasty – A pilot study
VL  - 24
IS  - 9
SP  - 1054
EP  - 1062
DO  - 10.1111/codi.16148
ER  - 

@article{
author = "Barišić, Goran and Anđelkov, Katarina and Rosić, Jovana and Miladinov, Marko and Kotur-Stevuljević, Jelena and Dinić, Tanja and Jelenković, Jelenko and Krivokapić, Zoran",
year = "2022",
abstract = "Aim: The aim of this study was to investigate whether the application of nanofat contain-ing stem cells improves continence in women who had previously undergone anal sphinc-teroplasty with unsatisfactory long-term outcomes.Method: This  prospective  pilot  study  included  nine  women  with  various  degrees  of  anal incontinence who had previously undergone anal sphincteroplasty due to obstetric trauma.  In  all  patients,  the  Wexner  Incontinence  Score  (WS)  and  Faecal  Incontinence  Quality of Life Score (FIQLS), as well as anal manometry and endoanal ultrasound meas-urements,  were  performed  before  the  procedure  and  during  follow-up.  In  all  patients,  liposuction  was  performed  and  50  ml  of  raw  lipoaspirate  was  obtained  and  processed  using a NanoFat Kit device. Approximately 20 ml of the mechanically emulsified and fil-trated fat was obtained and the anal sphincter complex was infiltrated with it. Patient fol-low-up was conducted in person or via telephone 6 and 12 months after the procedure.Results: The squeeze pressure was significantly increased 6 months after the proce-dure (p= 0.01). The external anal sphincter measured at the 12 o'clock position was sig-nificantly thicker (p= 0.04). A significant decrease in the WS was observed both 6 and 12 months after the procedure compared with baseline values (p< 0.05 for both).Conclusion: This  study  is  the  first  to  show  that  the  application  of  nanofat  as  an  inject-able  product  improves  continence  in  patients  with  unsatisfactory  results  after  sphinc-teroplasty, suggesting it to be a promising and effective therapeutic tool. The procedure is safe and can be easily performed as an ambulatory procedure.",
publisher = "John Wiley and Sons Inc",
journal = "Colorectal Disease",
title = "Application of nanofat for treatment of traumatic faecal incontinence after sphincteroplasty – A pilot study",
volume = "24",
number = "9",
pages = "1054-1062",
doi = "10.1111/codi.16148"
}

Barišić, G., Anđelkov, K., Rosić, J., Miladinov, M., Kotur-Stevuljević, J., Dinić, T., Jelenković, J.,& Krivokapić, Z.. (2022). Application of nanofat for treatment of traumatic faecal incontinence after sphincteroplasty – A pilot study. in Colorectal Disease
John Wiley and Sons Inc., 24(9), 1054-1062.
https://doi.org/10.1111/codi.16148

Barišić G, Anđelkov K, Rosić J, Miladinov M, Kotur-Stevuljević J, Dinić T, Jelenković J, Krivokapić Z. Application of nanofat for treatment of traumatic faecal incontinence after sphincteroplasty – A pilot study. in Colorectal Disease. 2022;24(9):1054-1062.
doi:10.1111/codi.16148 .

Barišić, Goran, Anđelkov, Katarina, Rosić, Jovana, Miladinov, Marko, Kotur-Stevuljević, Jelena, Dinić, Tanja, Jelenković, Jelenko, Krivokapić, Zoran, "Application of nanofat for treatment of traumatic faecal incontinence after sphincteroplasty – A pilot study" in Colorectal Disease, 24, no. 9 (2022):1054-1062,
https://doi.org/10.1111/codi.16148 . .